REGENXBIO (NASDAQ:RGNX) Raised to Hold at StockNews.com

REGENXBIO (NASDAQ:RGNX - Get Free Report) was upgraded by investment analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on Friday.

Other equities analysts also recently issued reports about the stock. HC Wainwright reiterated a "buy" rating and set a $36.00 price target on shares of REGENXBIO in a report on Wednesday, January 15th. Chardan Capital restated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a research note on Wednesday, November 20th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Morgan Stanley reissued an "overweight" rating and set a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. Finally, Raymond James initiated coverage on shares of REGENXBIO in a research report on Friday. They set an "outperform" rating and a $27.00 target price for the company. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, REGENXBIO currently has a consensus rating of "Moderate Buy" and a consensus target price of $33.45.

REGENXBIO Price Performance

Shares of REGENXBIO stock traded down $0.56 during trading hours on Friday, reaching $7.34. The company's stock had a trading volume of 683,697 shares, compared to its average volume of 1,024,742. The firm has a 50 day moving average price of $8.04 and a 200-day moving average price of $9.98. REGENXBIO has a one year low of $6.56 and a one year high of $28.80. The stock has a market cap of $363.38 million, a P/E ratio of -1.46 and a beta of 1.29.

Institutional Trading of REGENXBIO

Hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC increased its stake in shares of REGENXBIO by 141.3% in the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock worth $1,217,000 after acquiring an additional 67,948 shares during the period. Assenagon Asset Management S.A. grew its position in REGENXBIO by 53.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after buying an additional 296,700 shares during the period. BNP Paribas Financial Markets grew its position in REGENXBIO by 602.9% during the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company's stock valued at $214,000 after buying an additional 17,533 shares during the period. FMR LLC grew its position in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,656 shares during the period. Finally, Stifel Financial Corp grew its position in REGENXBIO by 13.3% during the third quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company's stock valued at $1,566,000 after buying an additional 17,563 shares during the period. Institutional investors and hedge funds own 88.08% of the company's stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.